Zoe Kopsaftis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zoe Kopsaftis has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Kristin Carson-Chahhoud
Adelaide Medical School; The University of Adelaide; Adelaide Australia
8 shared publications - Adrian Esterman
University of South Australia, Adelaide, Australia
3 shared publications Andrew Tai
3 shared publications- Helen Margaret Stallman
School of Psychology, Social Work and Social Policy, University of South Australia, Adelaide, South Australia, Australia
3 shared publications - Kelsey Sharrad
Adelaide Medical School; The University of Adelaide; Adelaide Australia
3 shared publications Nicola Spurrier
3 shared publications
Latest Publications
- Open Access
- 1 March 2022
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 41, 68-72
The modifiable biopsychosocial drivers of psychological distress for adolescents with asthma: Implications for Clinical Care
- 1 March 2022
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 41, 68-72
Open AccessThe modifiable biopsychosocial drivers of psychological distress for adolescents with asthma: Implications for Clinical Care
- Open Access
- 1 November 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Acceptability of mixed reality technology as a delivery mechanism for psychological intervention in adolescents with asthma: a qualitative study using the Theoretical Framework of Acceptability. (Preprint)
BACKGROUND Interactive, mixed-reality technologies such as augmented reality (AR), virtual reality (VR) and holographic technology may provide a novel, low-cost solution to fast-track the translation of evidence into practice; and may help overcome barriers to both mental health and asthma management service uptake. OBJECTIVE The aim of this study was to investigate if mixed reality technology is an acceptable mechanism for the delivery of a component of CBT for the management of symptoms of elevated psychological distress among young people with asthma. METHODS To explore the perceived acceptability of these technologies, mixed reality tools were evaluated via qualitative, one-on-one interviews with young people with asthma and symptoms of psychological distress, parents/caregivers of young people with asthma and symptoms of psychological distress, and relevant health professionals. The Theoretical Framework of Acceptability (TFA) was used for deductive coding of recorded interview transcripts. RESULTS Three young people with asthma and symptoms of psychological distress (2 female, mean age (years) = 14, SD= 1.73), four parents/caregivers of individuals with asthma (1 female, mean age (years) = 55, SD= 14.58) and six health professionals (4 females, mean age = 40.8, SD= 4.32) consented to participate. Four constructs – experienced affective attitude, experienced effectiveness, self-efficacy and intervention coherence – were coded in all participant transcripts. The most frequently coded constructs were experienced affective attitude and intervention coherence; both reported a total of 96 times, while the least frequently coded construct was anticipated opportunity cost; reported a total of 5 times. Participants were mostly positive about the mixed reality resources. However, some concerns were raised regarding ethicality, particularly in relation to privacy, accessibility, and messaging. Participants noted the need for technology to be used in conjunction with face-to-face engagement with health professionals, and that some patients would respond to this type of delivery mechanism better than others. CONCLUSIONS These results suggest that mixed reality technology for the purposes of delivery of psychological intervention may be an acceptable addition to current healthcare practices for young people with asthma and symptoms of psychological distress. CLINICALTRIAL The study was prospectively registered with the Australia and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620001109998.
- 1 November 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAcceptability of mixed reality technology as a delivery mechanism for psychological intervention in adolescents with asthma: a qualitative study using the Theoretical Framework of Acceptability. (Preprint)
BACKGROUND Interactive, mixed-reality technologies such as augmented reality (AR), virtual reality (VR) and holographic technology may provide a novel, low-cost solution to fast-track the translation of evidence into practice; and may help overcome barriers to both mental health and asthma management service uptake. OBJECTIVE The aim of this study was to investigate if mixed reality technology is an acceptable mechanism for the delivery of a component of CBT for the management of symptoms of elevated psychological distress among young people with asthma. METHODS To explore the perceived acceptability of these technologies, mixed reality tools were evaluated via qualitative, one-on-one interviews with young people with asthma and symptoms of psychological distress, parents/caregivers of young people with asthma and symptoms of psychological distress, and relevant health professionals. The Theoretical Framework of Acceptability (TFA) was used for deductive coding of recorded interview transcripts. RESULTS Three young people with asthma and symptoms of psychological distress (2 female, mean age (years) = 14, SD= 1.73), four parents/caregivers of individuals with asthma (1 female, mean age (years) = 55, SD= 14.58) and six health professionals (4 females, mean age = 40.8, SD= 4.32) consented to participate. Four constructs – experienced affective attitude, experienced effectiveness, self-efficacy and intervention coherence – were coded in all participant transcripts. The most frequently coded constructs were experienced affective attitude and intervention coherence; both reported a total of 96 times, while the least frequently coded construct was anticipated opportunity cost; reported a total of 5 times. Participants were mostly positive about the mixed reality resources. However, some concerns were raised regarding ethicality, particularly in relation to privacy, accessibility, and messaging. Participants noted the need for technology to be used in conjunction with face-to-face engagement with health professionals, and that some patients would respond to this type of delivery mechanism better than others. CONCLUSIONS These results suggest that mixed reality technology for the purposes of delivery of psychological intervention may be an acceptable addition to current healthcare practices for young people with asthma and symptoms of psychological distress. CLINICALTRIAL The study was prospectively registered with the Australia and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12620001109998.
- Top Cited Papers
- 19 April 2021
- Published by Springer Nature in Nature Human Behaviour
- Vol. 5 (5) , 631-652
A systematic review and meta-analysis of psychological interventions to improve mental wellbeing
Our current understanding of the efficacy of psychological interventions in improving mental states of wellbeing is incomplete. This study aimed to overcome limitations of previous reviews by examining the efficacy of distinct types of psychological interventions, irrespective of their theoretical underpinning, and the impact of various moderators, in a unified systematic review and meta-analysis. Four-hundred-and-nineteen randomized controlled trials from clinical and non-clinical populations (n = 53,288) were identified for inclusion. Mindfulness-based and multi-component positive psychological interventions demonstrated the greatest efficacy in both clinical and non-clinical populations. Meta-analyses also found that singular positive psychological interventions, cognitive and behavioural therapy-based, acceptance and commitment therapy-based, and reminiscence interventions were impactful. Effect sizes were moderate at best, but differed according to target population and moderator, most notably intervention intensity. The evidence quality was generally low to moderate. While the evidence requires further advancement, the review provides insight into how psychological interventions can be designed to improve mental wellbeing.
- 19 April 2021
- Published by Springer Nature in Nature Human Behaviour
- Vol. 5 (5) , 631-652
Top Cited PapersA systematic review and meta-analysis of psychological interventions to improve mental wellbeing
Our current understanding of the efficacy of psychological interventions in improving mental states of wellbeing is incomplete. This study aimed to overcome limitations of previous reviews by examining the efficacy of distinct types of psychological interventions, irrespective of their theoretical underpinning, and the impact of various moderators, in a unified systematic review and meta-analysis. Four-hundred-and-nineteen randomized controlled trials from clinical and non-clinical populations (n = 53,288) were identified for inclusion. Mindfulness-based and multi-component positive psychological interventions demonstrated the greatest efficacy in both clinical and non-clinical populations. Meta-analyses also found that singular positive psychological interventions, cognitive and behavioural therapy-based, acceptance and commitment therapy-based, and reminiscence interventions were impactful. Effect sizes were moderate at best, but differed according to target population and moderator, most notably intervention intensity. The evidence quality was generally low to moderate. While the evidence requires further advancement, the review provides insight into how psychological interventions can be designed to improve mental wellbeing.
- Open Access
- 1 January 2021
- Published by SAGE Publications in International Journal of Qualitative Methods
- Vol. 20
Mixed Reality Technology as a Delivery Mechanism for Psychological Intervention in Adolescents With Asthma: A Qualitative Protocol
Australia has one of the highest asthma prevalence rates in the world, with this chronic and debilitating condition affecting one in nine people. The health and mental wellbeing of young people with asthma are worse than not only their peers without asthma but also worse than that of people with asthma at other ages. Psychological interventions could be beneficial in treating symptoms of elevated psychological distress in patients with asthma. However, evidence suggests that engagement with mental health services is low in this population. Technology-based solutions that engage youth may overcome barriers to service uptake for both mental health and asthma management. To fast-track the successful translation of evidence-based treatment into practice, interactive, mixed-reality technologies such as augmented reality (AR), virtual reality (VR) and holographic technology may provide a novel, low-cost solution, yet to date, methodological rigor in the evaluation of mixed reality for this purpose is lacking. To evaluate the perceived usability and acceptability of these technologies, mixed reality tools will be developed by the author team to deliver a component of a psychological intervention for treatment of elevated psychological distress among young people with asthma. Qualitative research will be conducted through one-on-one interviews with young people with asthma, parents/caregivers of young people with asthma, and with health professionals, during which participants will have time to interact with the resources. Moderator guides will be used to direct interviews, and will be supplemented with a questionnaire, including Likert-type measures of usability and acceptability to facilitate triangulation of data. Understanding and data obtained through this study will be used to develop version 2.0 mixed reality tools, which will be tested for feasibility in a RCT. Improving access to and uptake of evidence-based treatments for elevated psychological distress in young people with asthma may reduce the burden of this highly prevalent disease.
- 1 January 2021
- Published by SAGE Publications in International Journal of Qualitative Methods
- Vol. 20
Open AccessMixed Reality Technology as a Delivery Mechanism for Psychological Intervention in Adolescents With Asthma: A Qualitative Protocol
Australia has one of the highest asthma prevalence rates in the world, with this chronic and debilitating condition affecting one in nine people. The health and mental wellbeing of young people with asthma are worse than not only their peers without asthma but also worse than that of people with asthma at other ages. Psychological interventions could be beneficial in treating symptoms of elevated psychological distress in patients with asthma. However, evidence suggests that engagement with mental health services is low in this population. Technology-based solutions that engage youth may overcome barriers to service uptake for both mental health and asthma management. To fast-track the successful translation of evidence-based treatment into practice, interactive, mixed-reality technologies such as augmented reality (AR), virtual reality (VR) and holographic technology may provide a novel, low-cost solution, yet to date, methodological rigor in the evaluation of mixed reality for this purpose is lacking. To evaluate the perceived usability and acceptability of these technologies, mixed reality tools will be developed by the author team to deliver a component of a psychological intervention for treatment of elevated psychological distress among young people with asthma. Qualitative research will be conducted through one-on-one interviews with young people with asthma, parents/caregivers of young people with asthma, and with health professionals, during which participants will have time to interact with the resources. Moderator guides will be used to direct interviews, and will be supplemented with a questionnaire, including Likert-type measures of usability and acceptability to facilitate triangulation of data. Understanding and data obtained through this study will be used to develop version 2.0 mixed reality tools, which will be tested for feasibility in a RCT. Improving access to and uptake of evidence-based treatments for elevated psychological distress in young people with asthma may reduce the burden of this highly prevalent disease.
- 27 February 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 58 (6) , 759-769
Pharmacological interventions for the treatment of psychological distress in patients with asthma: a systematic review and meta-analysis
OBJECTIVE: To evaluate the effectiveness and safety of pharmacological interventions for the treatment of psychological distress in people with asthma. DATA SOURCES: Electronic searches were performed in Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, PubMed/Medline, Embase, PsycInfo, Health Technology Assessment Database and Web of Science (inception to April 2019). STUDY SELECTIONS: Included studies were randomised controlled trials (RCT) or controlled clinical trials investigating the effect of pharmacological interventions for psychological distress in people with asthma. Records were screened and data extracted by two independent authors into standardised pilot-tested extraction templates. Data was analysed according to standard Cochrane methodology and entered into Review Manager Software version 5.3. RESULTS: From 5,689 studies, six RCTs (n = 215) met inclusion criteria and were included in the systematic review, of which four studies were included in the meta-analysis. A meta-analysis of four studies (n = 158) indicated no evidence of an effect for selective serotonin reuptake inhibitors (Citalopram or Escitalopram) on reduction of psychological distress in adult patients with asthma. Similarly, antiepileptic medication (Levetiracetam) was no better than placebo in the treatment of psychological distress in people with asthma. Adverse events were poorly reported across all studies but were slightly increased among intervention participants compared to control participants. CONCLUSIONS: There was great heterogeneity between studies and overall poor methodological quality providing insufficient evidence to make recommendations for or against the use of pharmacotherapy in asthma patients with psychological distress. Further confirmatory trials are warranted to make recommendations for clinical practice.
- 27 February 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 58 (6) , 759-769
Pharmacological interventions for the treatment of psychological distress in patients with asthma: a systematic review and meta-analysis
OBJECTIVE: To evaluate the effectiveness and safety of pharmacological interventions for the treatment of psychological distress in people with asthma. DATA SOURCES: Electronic searches were performed in Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, PubMed/Medline, Embase, PsycInfo, Health Technology Assessment Database and Web of Science (inception to April 2019). STUDY SELECTIONS: Included studies were randomised controlled trials (RCT) or controlled clinical trials investigating the effect of pharmacological interventions for psychological distress in people with asthma. Records were screened and data extracted by two independent authors into standardised pilot-tested extraction templates. Data was analysed according to standard Cochrane methodology and entered into Review Manager Software version 5.3. RESULTS: From 5,689 studies, six RCTs (n = 215) met inclusion criteria and were included in the systematic review, of which four studies were included in the meta-analysis. A meta-analysis of four studies (n = 158) indicated no evidence of an effect for selective serotonin reuptake inhibitors (Citalopram or Escitalopram) on reduction of psychological distress in adult patients with asthma. Similarly, antiepileptic medication (Levetiracetam) was no better than placebo in the treatment of psychological distress in people with asthma. Adverse events were poorly reported across all studies but were slightly increased among intervention participants compared to control participants. CONCLUSIONS: There was great heterogeneity between studies and overall poor methodological quality providing insufficient evidence to make recommendations for or against the use of pharmacotherapy in asthma patients with psychological distress. Further confirmatory trials are warranted to make recommendations for clinical practice.
- 14 January 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (1) , CD005534
Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease
Background Chronic obstructive pulmonary disease (COPD) is a global leading cause of morbidity and mortality, characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be partly caused by the administration of high inspired oxygen concentrations. Objectives To determine the effect of different inspired oxygen concentrations ("high flow" compared to "controlled") in the pre‐hospital setting (prior to casualty/emergency department) on outcomes for people with acute exacerbations of COPD (AECOPD). Search methods The Cochrane Airways Group Specialised Register, reference lists of articles and online clinical trial databases were searched. Authors of identified randomised controlled trials (RCTs) were also contacted for details of other relevant published and unpublished studies. The most recent search was conducted on 16 September 2019. Selection criteria We included RCTs comparing oxygen therapy at different concentrations or oxygen therapy versus placebo in the pre‐hospital setting for treatment of AECOPD. Data collection and analysis Two review authors independently assessed trial quality and extracted data. The primary outcome was all‐cause and respiratory‐related mortality. Main results The search identified a total of 824 citations; one study was identified for inclusion and two studies are awaiting classification. The 214 participants involved in the included study were adults with AECOPD, receiving treatment by paramedics en route to hospital. The mean age of participants was 68 years. A reduction in pre/in‐hospital mortality was observed in favour of the titrated oxygen group (two deaths in the titrated oxygen group compared to 11 deaths in the high‐flow control arm; risk ratio (RR) 0.22, 95% confidence interval (CI) 0.05 to 0.97; 214 participants). This translates to an absolute effect of 94 per 1000 (high‐flow oxygen) compared to 21 per 1000 (titrated oxygen), and a number needed to treat for an additional beneficial outcome (NNTB) of 14 (95% CI 12 to 355) with titrated oxygen therapy. Other than mortality, no other adverse events were reported in the included study. Wide confidence intervals were observed between groups for arterial blood gas (though this may be confounded by protocol infidelity in the included study for this outcome measure), treatment failure requiring invasive or non‐invasive ventilation or hospital utilisation. No data were reported for quality of life, lung function or dyspnoea. Risk of bias within the included study was largely unclear, though there was high risk of bias in domains relating to performance and attrition bias. We judged the evidence to be of low certainty, according to GRADE criteria. Authors' conclusions The one included study found a reduction in pre/in‐hospital mortality for the titrated oxygen arm compared to the high‐flow control arm. However, the paucity of evidence somewhat limits the reliability of these findings and generalisability to other settings. There is a need for robust, well‐designed RCTs to further investigate the effect of oxygen therapies in the pre‐hospital setting for people with AECOPD.
- 14 January 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (1) , CD005534
Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease
Background Chronic obstructive pulmonary disease (COPD) is a global leading cause of morbidity and mortality, characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be partly caused by the administration of high inspired oxygen concentrations. Objectives To determine the effect of different inspired oxygen concentrations ("high flow" compared to "controlled") in the pre‐hospital setting (prior to casualty/emergency department) on outcomes for people with acute exacerbations of COPD (AECOPD). Search methods The Cochrane Airways Group Specialised Register, reference lists of articles and online clinical trial databases were searched. Authors of identified randomised controlled trials (RCTs) were also contacted for details of other relevant published and unpublished studies. The most recent search was conducted on 16 September 2019. Selection criteria We included RCTs comparing oxygen therapy at different concentrations or oxygen therapy versus placebo in the pre‐hospital setting for treatment of AECOPD. Data collection and analysis Two review authors independently assessed trial quality and extracted data. The primary outcome was all‐cause and respiratory‐related mortality. Main results The search identified a total of 824 citations; one study was identified for inclusion and two studies are awaiting classification. The 214 participants involved in the included study were adults with AECOPD, receiving treatment by paramedics en route to hospital. The mean age of participants was 68 years. A reduction in pre/in‐hospital mortality was observed in favour of the titrated oxygen group (two deaths in the titrated oxygen group compared to 11 deaths in the high‐flow control arm; risk ratio (RR) 0.22, 95% confidence interval (CI) 0.05 to 0.97; 214 participants). This translates to an absolute effect of 94 per 1000 (high‐flow oxygen) compared to 21 per 1000 (titrated oxygen), and a number needed to treat for an additional beneficial outcome (NNTB) of 14 (95% CI 12 to 355) with titrated oxygen therapy. Other than mortality, no other adverse events were reported in the included study. Wide confidence intervals were observed between groups for arterial blood gas (though this may be confounded by protocol infidelity in the included study for this outcome measure), treatment failure requiring invasive or non‐invasive ventilation or hospital utilisation. No data were reported for quality of life, lung function or dyspnoea. Risk of bias within the included study was largely unclear, though there was high risk of bias in domains relating to performance and attrition bias. We judged the evidence to be of low certainty, according to GRADE criteria. Authors' conclusions The one included study found a reduction in pre/in‐hospital mortality for the titrated oxygen arm compared to the high‐flow control arm. However, the paucity of evidence somewhat limits the reliability of these findings and generalisability to other settings. There is a need for robust, well‐designed RCTs to further investigate the effect of oxygen therapies in the pre‐hospital setting for people with AECOPD.
- 31 October 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (10)
Community pharmacy personnel interventions for smoking cessation
Background Community pharmacists could provide effective smoking cessation treatment because they offer easy access to members of the community. They are well placed to provide both advice on the correct use of smoking cessation products and behavioural support to aid smoking cessation. Objectives To assess the effectiveness of interventions delivered by community pharmacy personnel to assist people to stop smoking, with or without concurrent use of pharmacotherapy. Search methods We searched the Cochrane Tobacco Addiction Group Specialised Register, along with clinicaltrials.gov and the ICTRP, for smoking cessation studies conducted in a community pharmacy setting, using the search terms pharmacist* or pharmacy or pharmacies. Date of the most recent search: January 2019. Selection criteria Randomised controlled trials of interventions delivered by community pharmacy personnel to promote smoking cessation amongst their clients who were smokers, compared with usual pharmacy support or any less intensive programme. The main outcome measure was smoking cessation rates at six months or more after the start of the intervention. Data collection and analysis We used standard methodological procedures expected by Cochrane for study screening, data extraction and management. We conducted a meta‐analysis using a Mantel‐Haenszel random‐effects model to generate risk ratios (RRs) and 95% confidence intervals (CIs). Main results We identified seven studies including 1774 participants. We judged three studies to be at high risk of bias and four to be at unclear risk. Each study provided face‐to‐face behavioural support delivered by pharmacy staff, and required pharmacy personnel training. Typically such programmes comprised support starting before quit day and continuing with weekly appointments for several weeks afterwards. Comparators were either minimal or less intensive behavioural support for smoking cessation, typically comprising a few minutes of one‐off advice on how to quit. Participants in both intervention and control arms received equivalent smoking cessation pharmacotherapy in all but one study. All studies took place in high‐income countries, and recruited participants visiting pharmacies. We pooled six studies of 1614 participants and detected a benefit of more intensive behavioural smoking cessation interventions delivered by community pharmacy personnel compared with less intensive cessation interventions at longest follow‐up (RR 2.30, 95% CI 1.33 to 3.97; I2 = 54%; low‐certainty evidence). Authors' conclusions Community pharmacists can provide effective behavioural support to people trying to stop smoking. However, this conclusion is based on low‐certainty evidence, limited by risk of bias and imprecision. Further research could change this conclusion.
- 31 October 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (10)
Community pharmacy personnel interventions for smoking cessation
Background Community pharmacists could provide effective smoking cessation treatment because they offer easy access to members of the community. They are well placed to provide both advice on the correct use of smoking cessation products and behavioural support to aid smoking cessation. Objectives To assess the effectiveness of interventions delivered by community pharmacy personnel to assist people to stop smoking, with or without concurrent use of pharmacotherapy. Search methods We searched the Cochrane Tobacco Addiction Group Specialised Register, along with clinicaltrials.gov and the ICTRP, for smoking cessation studies conducted in a community pharmacy setting, using the search terms pharmacist* or pharmacy or pharmacies. Date of the most recent search: January 2019. Selection criteria Randomised controlled trials of interventions delivered by community pharmacy personnel to promote smoking cessation amongst their clients who were smokers, compared with usual pharmacy support or any less intensive programme. The main outcome measure was smoking cessation rates at six months or more after the start of the intervention. Data collection and analysis We used standard methodological procedures expected by Cochrane for study screening, data extraction and management. We conducted a meta‐analysis using a Mantel‐Haenszel random‐effects model to generate risk ratios (RRs) and 95% confidence intervals (CIs). Main results We identified seven studies including 1774 participants. We judged three studies to be at high risk of bias and four to be at unclear risk. Each study provided face‐to‐face behavioural support delivered by pharmacy staff, and required pharmacy personnel training. Typically such programmes comprised support starting before quit day and continuing with weekly appointments for several weeks afterwards. Comparators were either minimal or less intensive behavioural support for smoking cessation, typically comprising a few minutes of one‐off advice on how to quit. Participants in both intervention and control arms received equivalent smoking cessation pharmacotherapy in all but one study. All studies took place in high‐income countries, and recruited participants visiting pharmacies. We pooled six studies of 1614 participants and detected a benefit of more intensive behavioural smoking cessation interventions delivered by community pharmacy personnel compared with less intensive cessation interventions at longest follow‐up (RR 2.30, 95% CI 1.33 to 3.97; I2 = 54%; low‐certainty evidence). Authors' conclusions Community pharmacists can provide effective behavioural support to people trying to stop smoking. However, this conclusion is based on low‐certainty evidence, limited by risk of bias and imprecision. Further research could change this conclusion.
- Open Access
- 29 November 2018
- Published by Springer Nature in Systematic Reviews
- Vol. 7 (1) , 1-13
Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
Currently, there is a lack of guidelines for the use of short-acting bronchodilators (SABD) in people admitted to hospital for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), despite routine use in practice and risk of cardiac adverse events. To review the evidence that underpins use and optimal dose, in terms of risk versus benefit, of SABD for inpatient management of AECOPD and collate the results for future guidelines. Medline, Embase, the Cochrane Central Register of Controlled Trials, clinicaltrials.gov and International Clinical Trials Registry Platform were searched (inception to November 2017) for published and ongoing studies. Included studies were randomised controlled trials or controlled clinical trials investigating the effect of SABD (β2-agonist and/or ipratropium) on inpatients with a diagnosis of AECOPD. This review was undertaken in accordance with PRISMA guidelines and a pre-defined protocol. Due to heterogeneous methodologies, meta-analysis was not possible so the results were synthesised qualitatively. Of 1378 studies identified, 10 met inclusion criteria. Narrative synthesis of 10 studies revealed no significant differences in most outcomes of interest relative to dose, delivery via inhaler or nebuliser, and type of β2-agonist used. However, some evidence demonstrated significantly increased cardiac side effects with increased dosage of β2-agonist (45% versus 24%), P<0.05). This review identified a paucity of methodologically rigorous evidence evaluating use of SABD among AECOPD. The available evidence did not identify any additional benefits for participants receiving higher doses of short-acting β2-agonists compared to lower doses, or based on type of delivery method or β2-agonists used. However, there was a small increase in some adverse events for participants using higher doses of β2-agonists.
- 29 November 2018
- Published by Springer Nature in Systematic Reviews
- Vol. 7 (1) , 1-13
Open AccessShort-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systematic review
Currently, there is a lack of guidelines for the use of short-acting bronchodilators (SABD) in people admitted to hospital for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), despite routine use in practice and risk of cardiac adverse events. To review the evidence that underpins use and optimal dose, in terms of risk versus benefit, of SABD for inpatient management of AECOPD and collate the results for future guidelines. Medline, Embase, the Cochrane Central Register of Controlled Trials, clinicaltrials.gov and International Clinical Trials Registry Platform were searched (inception to November 2017) for published and ongoing studies. Included studies were randomised controlled trials or controlled clinical trials investigating the effect of SABD (β2-agonist and/or ipratropium) on inpatients with a diagnosis of AECOPD. This review was undertaken in accordance with PRISMA guidelines and a pre-defined protocol. Due to heterogeneous methodologies, meta-analysis was not possible so the results were synthesised qualitatively. Of 1378 studies identified, 10 met inclusion criteria. Narrative synthesis of 10 studies revealed no significant differences in most outcomes of interest relative to dose, delivery via inhaler or nebuliser, and type of β2-agonist used. However, some evidence demonstrated significantly increased cardiac side effects with increased dosage of β2-agonist (45% versus 24%), P<0.05). This review identified a paucity of methodologically rigorous evidence evaluating use of SABD among AECOPD. The available evidence did not identify any additional benefits for participants receiving higher doses of short-acting β2-agonists compared to lower doses, or based on type of delivery method or β2-agonists used. However, there was a small increase in some adverse events for participants using higher doses of β2-agonists.
- 26 June 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (6) , CD002733
Influenza vaccine for chronic obstructive pulmonary disease (COPD)
Influenza vaccinations are currently recommended in the care of people with COPD, but these recommendations are based largely on evidence from observational studies, with very few randomised controlled trials (RCTs) reported. Influenza infection causes excess morbidity and mortality in people with COPD, but there is also the potential for influenza vaccination to cause adverse effects, or not to be cost effective. To determine whether influenza vaccination in people with COPD reduces respiratory illness, reduces mortality, is associated with excess adverse events, and is cost effective. We searched the Cochrane Airways Trials Register, two clinical trials registries, and reference lists of articles. A number of drug companies we contacted also provided references. The latest search was carried out in December 2017. RCTs that compared live or inactivated virus vaccines with placebo, either alone or with another vaccine, in people with COPD. Two review authors independently extracted data. All entries were double-checked. We contacted study authors and drug companies for missing information. We used standard methods expected by Cochrane. We included 11 RCTs with 6750 participants, but only six of these included people with COPD (2469 participants). The others were conducted on elderly and high-risk individuals, some of whom had chronic lung disease. Interventions compared with placebo were inactivated virus injections and live attenuated intranasal virus vaccines. Some studies compared intra-muscular inactivated vaccine and intranasal live attenuated vaccine with intra-muscular inactivated vaccine and intranasal placebo. Studies were conducted in the UK, USA and Thailand. Inactivated vaccine reduced the total number of exacerbations per vaccinated participant compared with those who received placebo (mean difference (MD) –0.37, 95% confidence interval (CI) –0.64 to –0.11; P = 0.006; two RCTs, 180 participants; low quality evidence). This was due to the reduction in 'late' exacerbations, occurring after three or four weeks (MD –0.39, 95% CI –0.61 to –0.18; P = 0.0004; two RCTs, 180 participants; low quality evidence). Both in people with COPD, and in older people (only a minority of whom had COPD), there were significantly more local adverse reactions in people who had received the vaccine, but the effects were generally mild and transient. There was no evidence of an effect of intranasal live attenuated virus when this was added to inactivated intramuscular vaccination. Two studies evaluating mortality for influenza vaccine versus placebo were too small to have detected any effect on mortality. However, a large study (N=2215) noted that there was no difference in mortality when adding live attenuated virus to inactivated virus vaccination, It appeared, from the limited number of RCTs we were able to include, all of which were more than a decade old, that inactivated vaccine reduced exacerbations in people with COPD. The size of effect was similar to that seen in large observational studies, and was due to a reduction in exacerbations occurring three or more weeks after vaccination, and due to influenza. There was a mild increase in transient local adverse effects with vaccination, but no evidence of an increase in early exacerbations. Addition of live attenuated virus to the inactivated vaccine was not shown to confer additional benefit.
- 26 June 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (6) , CD002733
Influenza vaccine for chronic obstructive pulmonary disease (COPD)
Influenza vaccinations are currently recommended in the care of people with COPD, but these recommendations are based largely on evidence from observational studies, with very few randomised controlled trials (RCTs) reported. Influenza infection causes excess morbidity and mortality in people with COPD, but there is also the potential for influenza vaccination to cause adverse effects, or not to be cost effective. To determine whether influenza vaccination in people with COPD reduces respiratory illness, reduces mortality, is associated with excess adverse events, and is cost effective. We searched the Cochrane Airways Trials Register, two clinical trials registries, and reference lists of articles. A number of drug companies we contacted also provided references. The latest search was carried out in December 2017. RCTs that compared live or inactivated virus vaccines with placebo, either alone or with another vaccine, in people with COPD. Two review authors independently extracted data. All entries were double-checked. We contacted study authors and drug companies for missing information. We used standard methods expected by Cochrane. We included 11 RCTs with 6750 participants, but only six of these included people with COPD (2469 participants). The others were conducted on elderly and high-risk individuals, some of whom had chronic lung disease. Interventions compared with placebo were inactivated virus injections and live attenuated intranasal virus vaccines. Some studies compared intra-muscular inactivated vaccine and intranasal live attenuated vaccine with intra-muscular inactivated vaccine and intranasal placebo. Studies were conducted in the UK, USA and Thailand. Inactivated vaccine reduced the total number of exacerbations per vaccinated participant compared with those who received placebo (mean difference (MD) –0.37, 95% confidence interval (CI) –0.64 to –0.11; P = 0.006; two RCTs, 180 participants; low quality evidence). This was due to the reduction in 'late' exacerbations, occurring after three or four weeks (MD –0.39, 95% CI –0.61 to –0.18; P = 0.0004; two RCTs, 180 participants; low quality evidence). Both in people with COPD, and in older people (only a minority of whom had COPD), there were significantly more local adverse reactions in people who had received the vaccine, but the effects were generally mild and transient. There was no evidence of an effect of intranasal live attenuated virus when this was added to inactivated intramuscular vaccination. Two studies evaluating mortality for influenza vaccine versus placebo were too small to have detected any effect on mortality. However, a large study (N=2215) noted that there was no difference in mortality when adding live attenuated virus to inactivated virus vaccination, It appeared, from the limited number of RCTs we were able to include, all of which were more than a decade old, that inactivated vaccine reduced exacerbations in people with COPD. The size of effect was similar to that seen in large observational studies, and was due to a reduction in exacerbations occurring three or more weeks after vaccination, and due to influenza. There was a mild increase in transient local adverse effects with vaccination, but no evidence of an increase in early exacerbations. Addition of live attenuated virus to the inactivated vaccine was not shown to confer additional benefit.
- Open Access
- 1 January 2018
- Published by The Australia and New Zealand School of Government (ANZSOG) in Evidence Base
- Vol. 2018 (1)
Cessation for smokers seeking treatment and advice from health care professionals in the hospital setting
Cigarette smoking costs Australia and New Zealand billions of dollars per year and is the single most preventable risk to health. Though governments have initiated numerous public health policies which have reduced the incidence of smoking, current usage remains around 15 percent. Making further inroads is likely to require augmenting these interventions with action at the individual level. The hospital setting provides a unique opportunity to assess the efficacy of individual attention. The aim of this study is to make an initial assessment of this efficacy by collating the existing evidence of outcomes achieved by health professionals working with individuals in hospital settings. The systematic literature search resulted in 69 studies (72 citations) for evaluation. Results indicated that a multi-component intervention comprised of high intensity counselling with a minimum of one month of post-discharge follow-up in addition to either nicotine replacement therapy or varenicline tartrate is the most effective combination of individual treatments for improving smoking abstinence, particularly for general inpatients. Further, there was an indication that patients admitted to specialist wards (e.g. cardiovascular) would benefit most from high intensity interventions, regardless of the use of adjunct pharmacotherapy. The evidence for a positive effect on sustained quit smoking rates for peri-operative patients is not definite, but as smoking adversely affects surgical success, implementing multicomponent interventions should still be considered. This review found no clear evidence to support implementation of smoking cessation interventions in the emergency department setting. Overall, interventions throughout the review were heterogeneous, making the estimate of a true effect difficult. Furthermore, there were only low numbers of local studies, with the findings of this review relying mostly upon extrapolation from overseas studies. Given the severity of the burden placed on the health system by smoking, there is a need for continuing endeavours by researchers with the support of the government to identify innovative and effective interventions for smokers that can be delivered by health professionals caring for smokers in the hospital setting.
- 1 January 2018
- Published by The Australia and New Zealand School of Government (ANZSOG) in Evidence Base
- Vol. 2018 (1)
Open AccessCessation for smokers seeking treatment and advice from health care professionals in the hospital setting
Cigarette smoking costs Australia and New Zealand billions of dollars per year and is the single most preventable risk to health. Though governments have initiated numerous public health policies which have reduced the incidence of smoking, current usage remains around 15 percent. Making further inroads is likely to require augmenting these interventions with action at the individual level. The hospital setting provides a unique opportunity to assess the efficacy of individual attention. The aim of this study is to make an initial assessment of this efficacy by collating the existing evidence of outcomes achieved by health professionals working with individuals in hospital settings. The systematic literature search resulted in 69 studies (72 citations) for evaluation. Results indicated that a multi-component intervention comprised of high intensity counselling with a minimum of one month of post-discharge follow-up in addition to either nicotine replacement therapy or varenicline tartrate is the most effective combination of individual treatments for improving smoking abstinence, particularly for general inpatients. Further, there was an indication that patients admitted to specialist wards (e.g. cardiovascular) would benefit most from high intensity interventions, regardless of the use of adjunct pharmacotherapy. The evidence for a positive effect on sustained quit smoking rates for peri-operative patients is not definite, but as smoking adversely affects surgical success, implementing multicomponent interventions should still be considered. This review found no clear evidence to support implementation of smoking cessation interventions in the emergency department setting. Overall, interventions throughout the review were heterogeneous, making the estimate of a true effect difficult. Furthermore, there were only low numbers of local studies, with the findings of this review relying mostly upon extrapolation from overseas studies. Given the severity of the burden placed on the health system by smoking, there is a need for continuing endeavours by researchers with the support of the government to identify innovative and effective interventions for smokers that can be delivered by health professionals caring for smokers in the hospital setting.